Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909400 | 1.00 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KDM4EHPGDCA12 | |
| SCHEMBL25201307 | 0.93 | KDM4E (0.47) | ALDH1A1SMN1; SMN2KDM4EHPGDCA12 | |
| SCHEMBL30504341 | 0.93 | KDM4E (0.47) | ALDH1A1SMN1; SMN2KDM4EHPGDCA12 | |
| SCHEMBL3426314 | 0.84 | KDM4E (0.53) | ALDH1A1SMN1; SMN2KDM4EHPGDCA12 | |
| SCHEMBL7034913 | 0.84 | KDM4E (0.53) | ALDH1A1SMN1; SMN2KDM4EHPGDCA12 | |
| SCHEMBL22725084 | 0.82 | MAPT (0.42) | ALDH1A1SMN1; SMN2KDM4EIDO1LMNA | |
| SCHEMBL31748445 | 0.82 | MAPT (0.42) | ALDH1A1SMN1; SMN2KDM4EIDO1LMNA | |
| SCHEMBL13814616 | 0.78 | KDM4E (0.47) | ALDH1A1SMN1; SMN2KDM4EHPGDCA12 | |
| SCHEMBL7021184 | 0.78 | KDM4E (0.47) | ALDH1A1SMN1; SMN2KDM4EHPGDCA12 | |
| SCHEMBL13804376 | 0.78 | KDM4E (0.51) | ALDH1A1SMN1; SMN2KDM4EHPGDCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| CN-117736207-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-115362003-B | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012058671-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058671-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ALDH1A1 4095/4885SMN1; SMN2 4737/4885KDM4E 1748/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | ALDH1A1 4095/4885SMN1; SMN2 4737/4885KDM4E 1748/4885 |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | ALDH1A1 3589/4885SMN1; SMN2 1256/4885KDM4E 739/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ALDH1A1 4095/4885SMN1; SMN2 4737/4885KDM4E 1748/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ALDH1A1 4095/4885SMN1; SMN2 4737/4885KDM4E 1748/4885 |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | ALDH1A1 3589/4885SMN1; SMN2 1256/4885KDM4E 739/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3208/4885SMN1; SMN2 3857/4885KDM4E 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.